Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

A recent BMJ Oncology study screens the prevalence of prostate magnetic resonance imaging (MRI) lesions in men based on age rather than prostate-specific antigen (PSA) levels. Study: Prevalence of MRI ...

A deep learning model was as effective as radiologists in detecting clinically significant prostate cancer on multiparametric MRI, a retrospective study suggested. In an internal test set of 400 ...

MRI screening shows promise for predicting clinically significant prostate cancer (PCa) early on and independently of prostate-specific antigen (PSA) assessment. In a recent study published in BMJ ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...